PPIL3

Across TCGA pan-cancer cohorts, PPIL3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PPIL3 data layer compared with 17 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PPIL3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PPIL3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where PPIL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.744	0.479	.027	10	view →
LSCC	DFS	Quartile	All	0.812	1.000	.004	8	view →
UCEC	DFS	Median	All	0.930	0.786	.026	6	view →
HNSC	DFS	Median	II,III,IV	0.910	0.982	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PPIL3–CCRCC (DFS)

Open the CCRCC breakdown →